We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy

By LabMedica International staff writers
Posted on 25 Apr 2025

Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or Tumor-Node-Metastasis (TNM) cancer staging system, which helps determine the stage of cancer, and (2) the American Thyroid Association (ATA) risk classification system, which is used to categorize cancer risk. More...

These systems are vital for predicting patient survival and guiding treatment decisions. However, manually integrating the complex clinical data into these systems can be time-consuming and inefficient. Now, researchers have introduced the world’s first artificial intelligence (AI) model capable of classifying both the stage and risk category of thyroid cancer with remarkable accuracy, exceeding 90%. This innovative AI model, featured in the journal npj Digital Medicine, is set to significantly reduce pre-consultation preparation time for frontline clinicians by approximately 50%.

An interdisciplinary research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed, Hong Kong) developed an AI assistant that employs large language models (LLMs) such as ChatGPT and DeepSeek. These models are designed to understand and process human language, helping to analyze clinical documents and improve the accuracy and efficiency of thyroid cancer staging and risk classification. The model utilizes four offline, open-source LLMs—Mistral (Mistral AI), Llama (Meta), Gemma (Google), and Qwen (Alibaba)—to interpret free-text clinical documents. The AI model was trained using an open-access data set from the United States that included pathology reports from 50 thyroid cancer patients from The Cancer Genome Atlas Program (TCGA), with validation done using pathology reports from 289 TCGA patients and 35 pseudo cases created by endocrine surgeons.

By combining the outputs from all four LLMs, the research team was able to enhance the overall performance of the AI model, achieving an accuracy rate ranging from 88.5% to 100% in ATA risk classification and 92.9% to 98.1% in AJCC cancer staging. In addition to its high accuracy in extracting and analyzing complex information from pathology reports, operation records, and clinical notes, the AI model also drastically reduces doctors’ preparation time by nearly half compared to manual interpretation. A significant advantage of this model is its ability to operate offline, allowing it to be deployed locally without the need to share or upload sensitive patient data, thereby ensuring maximum patient privacy. The AI model’s versatility means it can be easily integrated into a variety of healthcare settings, both public and private, as well as in international healthcare and research institutions.

“In line with government’s strong advocacy of AI adoption in healthcare, as exemplified by the recent launch of LLM-based medical report writing system in the Hospital Authority, our next step is to evaluate the performance of this AI assistant with a large amount of real-world patient data,” said Dr. Carlos Wong, Honorary Associate Professor in the Department of Family Medicine and Primary Care, School of Clinical Medicine, HKUMed. “Once validated, the AI model can be readily deployed in real clinical settings and hospitals to help clinicians improve operational and treatment efficiency.”

Related Links:
HKUMed


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Glucose Tolerance Test
NERL Trutol
New
UHF RFID Tag & Inlay
AD-327 U9 ETSI Pure 95
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.